Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Cidara Therapeutics stock | $1.54

Learn how to easily invest in Cidara Therapeutics stock.

Cidara Therapeutics Inc is a biotechnology business based in the US. Cidara Therapeutics shares (CDTX) are listed on the NASDAQ and all prices are listed in US Dollars. Cidara Therapeutics employs 79 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Cidara Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CDTX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Cidara Therapeutics stock price (NASDAQ: CDTX)

Use our graph to track the performance of CDTX stocks over time.

Cidara Therapeutics shares at a glance

Information last updated 2021-10-23.
Latest market close$1.54
52-week range$1.46 - $3.15
50-day moving average $1.98
200-day moving average $1.97
Wall St. target price$6.04
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.03

Buy Cidara Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Cidara Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cidara Therapeutics price performance over time

Historical closes compared with the close of $1.54 from 2021-10-25

1 week (2021-10-16) N/A
1 month (2021-09-27) -34.47%
3 months (2021-07-27) 2.67%
6 months (2021-04-27) -29.68%
1 year (2020-10-26) -48.15%
2 years (2019-10-25) -17.20%
3 years (2018-10-26) 3.67
5 years (2016-10-26) 9.83

Cidara Therapeutics financials

Revenue TTM $41.4 million
Gross profit TTM $-55,950,000
Return on assets TTM -42.4%
Return on equity TTM -163.97%
Profit margin -113.11%
Book value $0.32
Market capitalisation $103.9 million

TTM: trailing 12 months

Shorting Cidara Therapeutics shares

There are currently 678,257 Cidara Therapeutics shares held short by investors – that's known as Cidara Therapeutics's "short interest". This figure is 4% up from 652,407 last month.

There are a few different ways that this level of interest in shorting Cidara Therapeutics shares can be evaluated.

Cidara Therapeutics's "short interest ratio" (SIR)

Cidara Therapeutics's "short interest ratio" (SIR) is the quantity of Cidara Therapeutics shares currently shorted divided by the average quantity of Cidara Therapeutics shares traded daily (recently around 283789.53974895). Cidara Therapeutics's SIR currently stands at 2.39. In other words for every 100,000 Cidara Therapeutics shares traded daily on the market, roughly 2390 shares are currently held short.

However Cidara Therapeutics's short interest can also be evaluated against the total number of Cidara Therapeutics shares, or, against the total number of tradable Cidara Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cidara Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Cidara Therapeutics shares in existence, roughly 10 shares are currently held short) or 0.014% of the tradable shares (for every 100,000 tradable Cidara Therapeutics shares, roughly 14 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cidara Therapeutics.

Find out more about how you can short Cidara Therapeutics stock.

Cidara Therapeutics share dividends

We're not expecting Cidara Therapeutics to pay a dividend over the next 12 months.

Cidara Therapeutics share price volatility

Over the last 12 months, Cidara Therapeutics's shares have ranged in value from as little as $1.46 up to $3.15. A popular way to gauge a stock's volatility is its "beta".

CDTX.US volatility(beta: 1.33)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cidara Therapeutics's is 1.3254. This would suggest that Cidara Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Cidara Therapeutics overview

Cidara Therapeutics, Inc. , a biotechnology company, focuses on the discovery, development, and commercialization of novel long-acting anti-infectives for the treatment and prevention of diseases in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop antiviral conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014.

Frequently asked questions

What percentage of Cidara Therapeutics is owned by insiders or institutions?
Currently 7.339% of Cidara Therapeutics shares are held by insiders and 37.298% by institutions.
How many people work for Cidara Therapeutics?
Latest data suggests 79 work at Cidara Therapeutics.
When does the fiscal year end for Cidara Therapeutics?
Cidara Therapeutics's fiscal year ends in December.
Where is Cidara Therapeutics based?
Cidara Therapeutics's address is: 6310 Nancy Ridge Drive, San Diego, CA, United States, 92121
What is Cidara Therapeutics's ISIN number?
Cidara Therapeutics's international securities identification number is: US1717571079
What is Cidara Therapeutics's CUSIP number?
Cidara Therapeutics's Committee on Uniform Securities Identification Procedures number is: 171757107

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site